諾德股份(600110.SH):部分董事、高管擬合計減持不超62.066萬股
格隆匯12月7日丨諾德股份(600110.SH)公佈,公司董事孫志芳、常務副總經理陳鬱弼、財務總監王麗雯、副總經理兼董事會祕書王寒朵、副總經理周啟倫,因個人資金需求,擬自公吿披露之日起15個交易日後的6個月內,按規定在不超過其所持公司股份25%的範圍內且根據其持有股份限售規定實施減持,減持價格按市場價格確定。上述減持主體計劃減持總股數不超過62.066萬股,不超過目前公司總股本的0.0355%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.